Thallion Pharmaceuticals Inc.
TSX : TLN

Thallion Pharmaceuticals Inc.

April 18, 2007 09:45 ET

Thallion Presents Data at the 2007 Annual Meeting of the American Association of Cancer Research on its Oncology Drug Candidates ECO-4601 and CAP-232

MONTREAL, QUEBEC--(CCNMatthews - April 18, 2007) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced that new data on its two anticancer drug candidates, ECO-4601 and CAP-232, have been presented in three poster presentations at the 98th Annual Meeting of the American Association for Cancer Research (AACR), held in Los Angeles April 14-19, 2007.

In two poster presentations, new data highlighting the dual activity of ECO-4601 are presented. The inhibition of the RAS pathway combined to the binding to the PBR (a receptor highly expressed in cancer cells) make ECO-4601 a unique targeted anticancer drug candidate that is now being tested in a Phase I/II clinical trial involving patients with refractory solid tumors, including pancreatic cancer and glioblastoma.

A third presentation is reporting the expression of M2PK in specific human tumor types. M2PK is a specific kinase involved in the glycolysis of cancer cells and has been identified as the primary target of CAP-232.

A copy of each poster presented is available on Thallion's web site: www.thallion.com.

Abstract Number 176: Expression profiling of M2PK in 19 different human tumor types.

Abstract Number 415: ECO-4601 inhibits the Ras MAPK signaling pathway by dislodging Ras from the cell plasma membrane.

Abstract Number 5167: ECO-4601, a novel anticancer drug and PBR ligand, induces apoptosis through caspases-mediated events.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX:TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Thallion's clinical-stage programs include: Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections; ECO-4601, a novel anticancer therapy which comes from nonpathogenic microorganisms; and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. Thallion has two proprietary technology platforms CellCarta, a discovery engine in proteomics, and DECIPHER®, a genomics-based discovery platform. Thallion Pharmaceuticals was formed on March 14, 2007 by the amalgamation of Ecopia and Caprion. Additional information about the Company can be obtained at www.thallion.com.

Forward-Looking Statements

This Press release contains "forward looking information" that is based on expectations, estimates and projections as of the date of this Press release. Often, but not always, such forward looking information can be identified by the use of forward looking words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward looking information in this Press release.

Examples of such forward looking information in this Press release include, but are not limited to, information with respect to (i) the amalgamation and the results expected to be achieved from the completion of the amalgamation of Ecopia BioSciences Inc. and Caprion Pharmaceuticals Inc.; (ii) the ability to raise future capital to fund the research and development activities of the Company; (iii) success and timely completion of clinical studies; (iv) the pursuit of clinical trials in the United States; (v) the potential of ECO-4601 as a chemotherapy against primary brain cancer; (vi) the potential of ECO-4601 in the treatment of breast, prostate, colon, lung, ovarian and pancreatic cancers; (vii) the identification of a second generation ECO-4601 compound; (viii) the identification of a non-ECO-4601 related compound as a candidate for another regulatory filing; (ix) the potential of Shigamabs in the treatment of Shigatoxin-producing bacterial infections; (x) the potential of CAP-232 in the treatment of solid tumor cancers; and (xi) the earning of revenues from the exercise of exclusivity options on out-licensed patent properties. Such forward looking information is based on a number of assumptions concerning future events and is therefore subject to a number of risks and uncertainties, many of which are outside the control of the Company. Actual results may therefore vary materially from the expectations expressed by the Company and depend on a number of factors. These factors include, but are not limited to: (i) risks related to the integration of acquisitions; (ii) the possibility of delays due to patient recruitment or continued participation in the Phase I trial; (iii) scientific uncertainties relating to the correlation between preclinical animal data and human clinical data; (iv) the safety and efficacy of ECO-4601 as a cancer treatment; (v) the safety and efficacy of Shigamabs as a treatment of Shigatoxin-producing bacterial infections; (vi) the safety and efficacy of CAP-232 in the treatment of solid tumor cancers; (vii) timely progress and completion of Phase I study; (viii) uncertainties related to the regulatory process for drug development; (ix) the ability for the Company to fund its future operations in light of the lack of operating revenues for the years to come; and (x) the impact of general economic conditions.

While the Company anticipates that subsequent events and developments may cause its views to change, it will not update this forward-looking information, except as required by law. This forward-looking information should not be relied upon as representing the views of the Company as of any date subsequent to the date of this Press release. The Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those current expectations described in forward looking information. However, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended and that could cause actual actions, events or results to differ materially from current expectations. There can be no assurance that forward looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. These factors are not intended to represent a complete list of the factors that could affect the Company. A more complete discussion of the risks and uncertainties facing the Company appears in the Joint Management Information Circular dated February 7, 2007, the 2006 Management's Discussion and Analysis of Financial Position and Results of Operations for fiscal 2006 and the 2006 Annual Information Form available at www.sedar.com.

Contact Information